Open AccessA phase I study of ABT ‐510 plus bevacizumab in advanced solid tumors
Author(s) -
Uronis Hope E.,
Cushman Stephanie M.,
Bendell Johanna C.,
Blobe Gerard C.,
Morse Michael A.,
Nixon Andrew B.,
Dellinger Andrew,
Starr Mark D.,
Li Haiyan,
Meadows Kellen,
Gockerman Jon,
Pang Herbert,
Hurwitz Herbert I.
Publication year - 2013
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.65
Subject(s) - bevacizumab , medicine , tolerability , angiogenesis , vascular endothelial growth factor , pharmacology , biomarker , angiogenesis inhibitor , oncology , chemotherapy , adverse effect , vegf receptors , chemistry , biochemistry
Targeting multiple regulators of tumor angiogenesis have the potential to improve treatment efficacy. Bevacizumab is a monoclonal antibody directed against vascular endothelial growth factor and ABT ‐510 is a synthetic analog of thrombospondin, an endogenous angiogenesis inhibitor. Dual inhibition may result in additional benefit. We evaluated the safety, tolerability, and efficacy of the combination of bevacizumab plus ABT ‐510 in patients with refractory solid tumors. We also explored the effects of these agents on plasma‐based biomarkers and wound angiogenesis. Thirty‐four evaluable subjects were enrolled and received study drug. Therapy was well tolerated; minimal treatment‐related grade 3/4 toxicity was observed. One patient treated at dose level 1 had a partial response and five other patients treated at the recommended phase II dose had prolonged stable disease for more than 1 year. Biomarker evaluation revealed increased levels of D‐dimer, von Willebrand factor, placental growth factor, and stromal‐derived factor 1 in response to treatment with the combination of bevacizumab and ABT ‐510. Data suggest that continued evaluation of combination antiangiogenesis therapies may be clinically useful.